The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Prospects: Histone deacetylase inhibitors
Open accessAbstract
Histone deacetylase (HDAC), inhibitors represent a new class of targeted anti‐cancer agents. Several of these compounds are in clinical trials with significant activity against a spectrum of both hematologic and solid tumors at doses that are well tolerated by the patients. The HDAC inhibitors are a structurally diverse group of molecules that can induce growth arrest, differentiation, apoptosis, and autophagocytic cell death of cancer cells. While the base sequence of DNA provides the genetic code for proteins, the expression of genes is regulated, in large part, by the structure of the chromatin proteins around which the DNA is wrapped (epigenetic gene regulation). The acetylation and deacetylation of the lysines in the tails of the core histones, among the most extensively studied aspects of chromatin structure, is controlled by the action of two families of enzymes, histone deacetylases (HDACs) and histone acetyltransferases (HATs). Protein components of transcription factor complexes and many other non‐histone proteins are also substrates for HDACs and HATs. The structure and activity of these non‐histone proteins may be altered by acetylation/deacetylation with consequent effects on various cell functions including gene expression, cell cycle progression, and cell death pathways. This review focuses on several key questions with respect to the mechanism of action of HDACi, including, what are the different cell phenotypes induced by HDACi, why are normal cells compared to transformed cells relatively resistant to HDACi induced cell death, why are certain tumors more responsive to HDACi than others, and what is the basis of the selectivity of HDACi in altering gene expression. The answers to these questions will have therapeutic importance since we will identify targets for enhancing the efficacy and safety of HDACi. © 2005 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
ACETYLATION AND METHYLATION OF HISTONES AND THEIR POSSIBLE ROLE IN THE REGULATION OF RNA SYNTHESIS
Allfrey, V. G., Faulkner, R., & Mirsky, A. E. (1964) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.51.5.786 · Cited by 2,639
Physiological functions of thioredoxin and thioredoxin reductase
Arnér, E. S. J., & Holmgren, A. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01701.x · Cited by 2,525
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Self-citationStructures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Self-citationZhang, Y., & Reinberg, D. (2001) · Genes & Development · doi:10.1101/gad.927301 · Cited by 1,530
The Sir2 Family of Protein Deacetylases
Blander, G., & Guarente, L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073651 · Cited by 1,495
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
Cited by
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Histone Deacetylase Inhibitors: Overview and Perspectives
Dokmanovic, M., Clarke, C., & Marks, P. A. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0324 · Cited by 1,164
Self-citationAlao, J. P. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-24 · Cited by 871
Chromatin Challenges during DNA Replication and Repair
Groth, A., Rocha, W., Verreault, A., & Almouzni, G. (2007) · Cell · doi:10.1016/j.cell.2007.01.030 · Cited by 741
Endoplasmic reticulum stress, obesity and diabetes
Cnop, M., Foufelle, F., & Velloso, L. A. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.07.010 · Cited by 682
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Mottamal, M., Zheng, S., Huang, T., & Wang, G. (2015) · Molecules · doi:10.3390/molecules20033898 · Cited by 680
Discovery and development of SAHA as an anticancer agent
Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210204 · Cited by 626
Self-citation(2011) · PubMed Central · Cited by 560
Rapid Alteration of MicroRNA Levels by Histone Deacetylase Inhibition
Scott, G. K., Mattie, M. D., Berger, C. E., Benz, S. C., & Benz, C. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3632 · Cited by 492
Epigenetic mechanisms in neurological disease
Jakovcevski, M., & Akbarian, S. (2012) · Nature Medicine · doi:10.1038/nm.2828 · Cited by 450
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Tan, J., Cang, S., Ma, Y., Petrillo, R. L., & Liu, D. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-5 · Cited by 425
Brain Chromatin Remodeling: A Novel Mechanism of Alcoholism
Pandey, S. C., Ugale, R., Zhang, H., Tang, L., & Prakash, A. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5731-07.2008 · Cited by 373
Clinical Studies of Histone Deacetylase Inhibitors
Prince, H. M., Bishton, M. J., & Harrison, S. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2785 · Cited by 356
Distribution of histone deacetylases 1–11 in the rat brain
Broide, R. S., Redwine, J. M., Aftahi, N., Young, W., Bloom, F. E., & Winrow, C. J. (2007) · Journal of Molecular Neuroscience · doi:10.1007/bf02686117 · Cited by 347
VanderMolen, K. M., McCulloch, W., Pearce, C. J., & Oberlies, N. H. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.35 · Cited by 333
HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation
Parmigiani, R. B., Xu, W. S., Venta-Perez, G., Erdjument-Bromage, H., Yaneva, M., Tempst, P., & Marks, P. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803749105 · Cited by 321
Self-citationThe role of Sp1 and Sp3 in normal and cancer cell biology
Li, L., & Davie, J. R. (2010) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2010.07.010 · Cited by 318
Histone deacetylase inhibitors: discovery and development as anticancer agents
Marks, P. A., & Dokmanovic, M. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.12.1497 · Cited by 318
Self-citationThomas, E. A., Coppola, G., Desplats, P. A., Tang, B., Soragni, E., Burnett, R., Gao, F., Fitzgerald, K. M., Borok, J. F., Herman, D., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804249105 · Cited by 291
Negative and Positive Regulation of Gene Expression by Mouse Histone Deacetylase 1
Zupkovitz, G., Tischler, J., Posch, M., Sadzak, I., Ramsauer, K., Egger, G., Grausenburger, R., Schweifer, N., Chiocca, S., Decker, T., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01220-06 · Cited by 263
Molecular pathogenesis of spinocerebellar ataxias
Duenas, A. M. (2006) · Brain · doi:10.1093/brain/awl081 · Cited by 260
Faraco, G., Pancani, T., Formentini, L., Mascagni, P., Fossati, G., Leoni, F., Moroni, F., & Chiarugi, A. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.027912 · Cited by 255
Inhibition of Histone Deacetylation: A Strategy for Tumor Radiosensitization
Camphausen, K., & Tofilon, P. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6202 · Cited by 162
Scuto, A., Kirschbaum, M., Kowolik, C., Kretzner, L., Juhasz, A., Atadja, P., Pullarkat, V., Bhatia, R., Forman, S., Yen, Y., et al. (2008) · Blood · doi:10.1182/blood-2007-10-117762 · Cited by 141
Yamawaki, Y., Fuchikami, M., Morinobu, S., Segawa, M., Matsumoto, T., & Yamawaki, S. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.585663 · Cited by 117
TBX3 Is Overexpressed in Breast Cancer and Represses p14ARF by Interacting with Histone Deacetylases
Yarosh, W., Barrientos, T., Esmailpour, T., Lin, L., Carpenter, P. M., Osann, K., Anton-Culver, H., & Huang, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5012 · Cited by 105
HDAC inhibitors: A new promising drug class in anti-aging research
Pasyukova, E. G., & Vaiserman, A. M. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.08.008 · Cited by 99
Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)
Witter, D. J., Harrington, P., Wilson, K. J., Chenard, M., Fleming, J. C., Haines, B., Kral, A. M., Secrist, J. P., & Miller, T. A. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.047 · Cited by 93
Suh, H.-S., Choi, S., Khattar, P., Choi, N., & Lee, S. C. (2010) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-010-9192-0 · Cited by 86
Yoo, D. Y., Kim, W., Nam, S. M., Kim, D. W., Chung, J. Y., Choi, S. Y., Yoon, Y. S., Won, M.-H., & Hwang, I. K. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0503-5 · Cited by 60
The histone deacetylase inhibitor entinostat/syndax 275 in osteosarcoma
Kiany, S., Harrison, D., & Gordon, N. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43032-0_7 · Cited by 24
Nasehi, L., Morassaei, B., Ghaffari, M., Sharafi, A., Dehpour, A. R., & Hosseini, M.-J. (2022) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2022-0098 · Cited by 5
Metadata
- Authors
- Dokmanovic, M., & Marks, P. A.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2005-08-08
- Volume
- 96
- Issue
- 2
- Pages
- 293-304
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W1996103159
- Cited by
- 479
- References
- 49
- FWCI
- 14.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.